Current Aspects in the Pathophysiology and Treatment of Chronic Wounds in Diabetes Mellitus by Tsourdi, Elena et al.
Hindawi Publishing Corporation
BioMed Research International
Volume 2013, Article ID 385641, 6 pages
http://dx.doi.org/10.1155/2013/385641
Review Article
Current Aspects in the Pathophysiology and Treatment of
Chronic Wounds in Diabetes Mellitus
Elena Tsourdi,1 Andreas Barthel,1,2 Hannes Rietzsch,1
Andreas Reichel,1 and Stefan R. Bornstein1
1 Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III, Technical University Medical Center,
01307 Dresden, Germany
2 Endokrinologikum Ruhr, 44866 Bochum, Germany
Correspondence should be addressed to Andreas Barthel; andreas.barthel@uniklinikum-dresden.de
Received 28 October 2012; Accepted 6 March 2013
Academic Editor: David G. Armstrong
Copyright © 2013 Elena Tsourdi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Impaired wound healing is a frequent and very severe problem in patients with diabetes mellitus, yet little is known about
the underlying pathomechanisms. In this paper we review the biology of wound healing with particular attention to the
pathophysiology of chronic wounds in diabetic patients. The standard treatment of diabetic ulcers includes measures to optimize
glycemic control as well as extensive debridement, infection elimination by antibiotic therapy based on wound pathogen cultures,
the use of moisture dressings, and offloading high pressure from the wound bed. In this paper we discuss novel adjuvant therapies
with particular reference to the use of autologous skin transplants for the treatment of diabetic foot ulcers which do not respond to
standard care.
1. Introduction
The diabetic foot syndrome is a very severe and common
complication in patients with diabetes mellitus with a cumu-
lative lifetime incidence of up to 25 percent [1].The escalating
high rates of diabetes in many parts of the world make
diabetic foot ulcers a major and increasing public-health
problem. Foot ulcers cause substantial morbidity, impair
quality of life, are the most important risk factor for lower-
extremity amputation, and result in high treatment costs
and enormous economic losses [2]. The factors that delay
wound healing in diabetes are multiple and relate both
to the impaired glucose metabolism and to the effect of
neurovascular complications. Diabetic foot ulcers readily
become chronic; all too often these wounds do not heal
primarily. Treatment of chronic wounds should be essentially
directed against the main etiologic factors responsible for
the wound. Management is based on the simple principles
of eliminating infection, the use of dressings to maintain
a moist wound bed and to absorb exsudate, offloading
high pressure from the wound bed, and debridement to
accelerate endogenous healing and facilitate the effectiveness
of topically applied substances [3]. Nevertheless, there are
often cases of persistent diabetic foot ulcers that do not
respond to standard care. In such patients, skin replacement
therapies either by autologous skin transplantation or by
tissue-engineered human skin equivalents are second-line
options which could prevent an amputation and should
therefore be considered.
2. Physiological Process of Wound Healing
The physiological process of wound healing is traditionally
divided into four phases: haemostasis, inflammation, pro-
liferation, and maturation or remodelling. These phases are
orchestrated by a subtle interplay of cellular and humoral fac-
tors [4]. Haemostasis occurs within an hour after injury and
is characterized by vasoconstriction and clotting. Platelets
not only initiate the clotting cascade but also secrete growth
factors and cytokines which initiate healing. The subsequent
inflammation phase takes up to seven days and is mediated
through neutrophil granulocytes which prevent bacterial
contamination and cleanse the wound from cell debris.
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Monocytes are attracted to the wound by chemotactic factors
and differentiate into wound macrophages. The latter not
only remove bacteria and nonviable tissue by phagocytosis
but also release various growth factors required to stimulate
fibroplasia and angiogenesis, thereby providing the basis for
the formation of the provisional extracellular matrix (ECM).
The proliferation phase is initiated at day 2 after injury and
takes up to 20 days. This phase is primarily characterized by
tissue granulation and formation of new blood vessels (angio-
genesis). The angiogenic process involves growth factors
such as platelet-derived growth factor (PDGF), macrophage
angiogenesis factor, and angiotensin. Concomitant epithe-
lialisation is then initiated to cover the granulation tissue
with a cellular barrier. The last phase involving extensive
tissue remodelling lasts from one week to six months after
injury. During that phase the provisional wound matrix is
replaced with proteoglycan and collagen molecules which
readily become organised into thicker bundles resulting in
stronger but more rigid scar tissue.
3. Pathophysiology of Wound
Healing in Diabetes
Woundhealing in diabetes is impaired by factors that are both
extrinsic and intrinsic to the wound and its biology. Extrinsic
factors include repeated trauma or mechanical stress applied
to a foot that has been rendered insensitive due to neuropathy
as well as ischemia as a result of macro- or microvascular dis-
ease [5]. Thickening of the basement membrane of the capil-
laries and arterioles frequently occurs in individuals with dia-
betes, resulting in an impaired wound healing and persistent
ulcer formation [6]. An important role has been attributed
to factors intrinsic to the biology of the chronic wound in
diabetes. It has been postulated that hyperglycaemia itself
has a deleterious effect on wound healing through the
formation of advanced glycation end-products (AGEs) which
induce the production of inflammatory molecules (TNF-𝛼,
IL-1) and interfere with collagen synthesis [7]. Furthermore,
Spravchikov et al. showed that exposure to high glucose is
associated with changes in cellular morphology, decreased
proliferation, and abnormal differentiation of keratinocytes
[8], thus revealing another mechanism by which hypergly-
caemia may affect wound healing in diabetes. Interestingly,
the healing times of leg and foot ulcers are decreased in
diabetic patients with lower HbA1c, thereby emphasizing the
clinical correlation between hyperglycaemia and impaired
wound healing [9]. An altered immune function may also
contribute to poor wound healing in patients with diabetes.
Decreased chemotaxis, phagocytosis, bacterial killing [10],
and reduced heat shock protein expression [11] have been
implicated in the early phase of wound healing in diabetes.
Fahey et al. demonstrated that altered leukocyte infiltration
and wound fluid IL-6 characterize the late inflammatory
phases of wound healing in diabetes [12]. It therefore seems
that an altered pattern of cytokine appearance in the wound
milieu may contribute to delayed wound healing in diabetes.
This is substantiated by the fact that altered bioavailability
of cytokines and growth factors have been implicated in the
pathogenesis of chronic wounds. These signalling molecules
are secreted by various cell types to control cellular prolifer-
ation, differentiation, migration, and metabolism. Abnormal
expression of growth factors has been observed in diabetic
foot ulcers [13]. It has been postulated that trapping of growth
factors and cytokines by certain macromolecules such as
albumin, fibrinogen, and 𝛽2-macroglobulin may disrupt the
healing process [14]. Furthermore, increased degradation of
growth factors in wound fluid of diabetic subjects has been
discussed as a factor contributing to an impaired wound
healing process. For example, Duckworth et al. have reported
an increased activity of insulin degrading enzyme (IDE)
activity in wound fluid from patients with diabetic foot
ulcers [15]. Interestingly, insulin degrading activity in the
wound fluidwas found to be positively correlatedwithHbA1c
levels, thereby supporting the fact that glucose control is
an essential prerequisite for wound healing. In addition,
normal wound healing requires a balance between the accu-
mulation of collagenous and noncollagenous extracellular
matrix components. Their remodelling is determined by
matrix metalloproteinases (MMPs) and the tissue inhibitors
of metalloproteinases (TIMPs) [16]. MMPs play essential
roles in initial wound debridement as well as in angiogenesis,
epithelialization, and remodelling of scar tissue [17]. Several
studies reported elevated levels of MMPs and reduced levels
of TIMPs in chronic wounds [18] with a similar pattern in
wounds of patients with diabetes mellitus [19]. Last but not
least, there is also increasing evidence that the resident cells
of chronic wounds may undergo phenotypic changes that
impair their capacity for proliferation and movement. For
example, it has been reported that fibroblasts from venous
and pressure ulcers are senescent and have a diminished
ability to proliferate with the proliferative capacity being
directly correlated to the failure to heal [20].
4. Standard Treatment Methods in
Diabetic Foot Ulcers
The standard treatment of diabetic ulcers includes measures
to assess vascular status and optimize glycemic control as well
as extensive debridement, infection elimination by antibiotic
therapy based on wound pathogen cultures, the use of
moisture dressings, and offloading high pressure from the
wound bed. Vascular assessment should include palpation
of all lower-extremity pulses, including femoral, popliteal,
posterior tibial, and dorsalis pedis pulses. A surrogative and
more accurate method of diagnosing vascular insufficiency
in the lower limbs is the use of the ankle branchial pressure
index (ABPI), the results of which can be validated through
Doppler waveform and pulse oximetry. In case of signifi-
cant peripheral arterial disease, therapeutic revascularisation
should be undertaken, since adequate vascular supply is
essential for wound healing. The correlation between nor-
moglycaemia and facilitated wound healing in diabetes has
been discussed in the previous section. The pivotal role of
surgical debridement in healing of diabetic foot ulcers is
widely acknowledged [21]. The rationale lies in removing
necrotic, devitalized wound bed and wound edge tissue that
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inhibits healing, so that secondary wound healing can be
achieved [22]. The determination of organisms responsible
for a diabetic foot infection via culture of appropriately
collected tissue specimens enables clinicians tomake optimal
antibiotic choices based on culture and sensitivity results
[23]. A recent meta-analysis of randomized controlled trials
(RCTs) comparing the effects of different types of wound
dressings in the treatment of diabetic foot ulcers found no
significant differences between them so that aspects such
as the dressing cost and the wound properties should be
consideredwhenmaking a decision [24]. A strong association
between the efficacy to offload the foot and clinical outcome
is supported through evidence-based guidelines [25].
5. Additional Current Treatment Methods in
Persistent Diabetic Foot Ulcers
5.1. Autologous Skin Transplantation in Diabetic Foot Ulcers.
Flaps and grafts are the two principal surgical procedures
for skin tissue replacement. A flap is a full-thickness portion
of skin sectioned and isolated peripherally and in depth
from the surrounding skin, except along one side, called the
peduncle. A graft is a section of skin of variable thicknesses
and sizes completely detached from its original site and used
to cover the zone to be repaired. Particular attention should
be paid to mesh grafts which are obtained by passing a
whole dermoepidermal explant through a special surgical
tool (mesher), thereby increasing the initial surface area of the
explanted skin [26]. Skin grafts are traditionally used in the
treatment of severe burns. However, a number of studies have
recently reported successful managing of large tissue defects
in patients with diabetic foot ulcers with microsurgical grafts
[27–29]. The process of graft adoption is defined as the
adhesion of the graft skin to the recipient wound area and
its subsequent vascularization. This process is identical to
that of wound healing. Following an initial rejection phase
after the skin grafting procedure with massive inflammation,
revascularization of the graft starts after 24 to 48 hours.
Initially the graft is pale and white but subsequently adopts a
pinkish colour which indicates successful adoption in associ-
ation with firm attachment to the bed. Apart from immune
compatibility, basic conditions for graft taking encompass
the ability for neoangiogenesis, good adherence of the graft
to recipient areas, and hence accurate immobilization of the
graft. A graft can only be placed to vital exposed dermis
capable of producing granulation tissue. The recipient area
must not be infected or excessively exudative. In addition
well-functioning haemostasis is required. In fact, any accu-
mulation of exudate or blood underneath the graft jeopar-
dizes its survival as it impedes adherence and penetration of
new capillaries. The consequent handling of the transplant is
of utter importance. In the first weeks after transplantation,
complete removal of pressure is essential. Protective footwear
with dully formed inserts can secure adequate offloading of
the area of high pressure and protect the transplant.
5.2. Tissue-Engineered Human Skin Equivalents in Diabetic
Foot Ulcers. In the recent years much attention has been paid
to the use of tissue-engineered human skin equivalents in
the treatment of diabetic foot ulcers. The first engineered
skin substitutes were matrix-based products consisting of
cross-linked collagen and glycosaminoglycans. The matrix
eventually undergoes degradation, while simultaneously the
host’s cells invade and proliferate within it. Integra, a prod-
uct of this category, has shown promising results in deep
wounds [30]. The second generation of tissue-engineered
skin equivalents consisted of cell-based products, mostly
keratinocytes. Marston et al. demonstrated that dermagraft,
a cryopreserved human fibroblast-derived dermal substitute,
is a safe and effective treatment for diabetic foot ulcers
[31]. Veves et al. showed that the application of graft skin
(Apligraf)—a human skin equivalent manufactured from
cultured living dermis and sequentially cultured epider-
mis of neonatal foreskins—results in significantly improved
healing compared to other available treatments. Moreover,
there were no significant side effects [32]. Nevertheless,
both products are ultimately rejected, so that their primary
task appears to be a transient restoration of the dermis
until the patients’ keratinocytes can migrate and close the
wound.
5.3. Bone Marrow-Derived Cells. Another very promising
therapeutic option involves the use of bone marrow-derived
cells, and recent evidence indicates that bone marrow con-
tains stem cells with the potential for differentiation into
a variety of tissues. For example, patients with diabetes
are known to have an impaired mobilization of endothelial
progenitor cells (EPCs) in the bone marrow and decreased
accumulation of these cells in wounds [33, 34]. Bonemarrow-
derived cells may thus be a valuable and unlimited source
of progenitor and/or stem cells [35]. For example, Badiavas
and Falanga described that the local application of autologous
bone marrow-derived cells resulted in complete wound
closure in 3 patients unresponsive to standard therapies
including bioengineered skin application and autologous skin
grafting [36].
Furthermore, it is assumed that hyperbaric oxygen results
in EPC recruitment but does not improve migration of EPC
to the wound site. However, in a murine model of diabetes
coadministration of stromal cell-derived factor-1-alpha (SDF-
1𝛼) resulted in homing of the activated EPCs to the wound
site [37]. These data suggest that combining oxygen therapy
with SDF-1𝛼 may improve wound healing in patients with
diabetes.
Another novel interesting approach consists of lineage
commitment of stem cells to the keratinocyte lineage. This
can be achieved through exposure of the stem cells to
a mixture of cytokines, growth factors, and extracellular
matrix components in vitro and has been attempted with
only moderate success [38, 39]. Another method is through
genetic modulation, in particular transfection of stem cells
with recombinant DNA encoding for proteins that regulate
the commitment to the keratinocyte lineage [40]. Although
this method presents with exciting new potential, one cannot
overlook the potential detrimental effects and safety concerns
of genetic manipulation of stem cells [41].
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Diabetic foot ulcer
Initial assessment
Physical examination
Digital photography
Objective measurement
Assessment of arterial blood supply
(foot pulses, noninvasive vascular assessment with
ankle-branchial pressure index and duplex ultrasonography)
- No clinically significant arterial obstruction
(neuropathic foot ulcer)
- Treat any infection (obtain specimen for culture
and provide appropriate antibiotics)
- Eliminate pressure with minimizing mobilisation
- Perform sharp debridement
Healing at 4 weeks
Yes No
- Educate patient about wearing appropriate
shoes/checking for signs or problems
- Provide regular followup
Consider
adjuvant care
- Clinically significant arterial disease
(angiopathic/angioneuropathic foot ulcer)
- Treat any infection
- Provide referral for vascular care
Topical biological therapy (PDGF).
Vacuum-assisted closure (VAC) negative pressure 
Autologous skin transplantaion
Hyperbaric oxygen
Human skin equivalents (apligraf, dermagraft)
stem cells
Figure 1: Algorithm for the management of diabetic foot ulcers.
5.4. Growth Factors. Of the known growth factors with a
proposed role inwoundhealing, therapeutic efficacy has been
demonstrated only for becaplermin (recombinant human
platelet-derived growth factor, Regranex) in several ran-
domized controlled clinical trials [42]. Nevertheless, recent
data reported an increased cancer risk in patients treated
with more than three tubes of becaplermin so that pending
lower follow-up data on the potential risk of malignancy
in connection with its use this agent should be used with
extreme caution in patients with diagnosed malignancy [43].
5.5. Subatmospheric Pressure Dressings. The use of subatmo-
spheric pressure dressings such as the commercially available
vacuum-assisted closure (VAC) device have been shown to
be an effective way in accelerating the healing of various
wounds. This technique optimizes blood flow, decreases
local tissue edema, and removes excessive fluid from the
wound bed. Additionally, the cyclical application of sub-
atmospheric pressure alters the cytoskeleton of the cells in
the wound bed thereby triggering a cascade of intercellular
signals that increases the rate of cell division and formation
of granulation tissue. The success rate of skin grafting is
significantly increased when VAC is used as bolster covering
the freshly skin-grafted wound [44, 45]. A recent review
assessing current modalities in the treatment of diabetic foot
ulcers [46] concluded that although vacuum compression
therapy has been linked to significant reduction in wound
area [47] and time to healing [48], this treatment was not
shown to be costeffective and should therefore be used only
in exceptional circumstances [49].
6. Perspectives and Conclusion
The treatment of diabetic foot ulcers is a constant challenge
in diabetes care and requires a multidisciplinary approach
involving doctors, physiotherapists, specialised podologists,
and orthopedic technicians. Over the recent years, novel
and promising therapeutic options have emerged for the
treatment of chronic diabetic foot ulcers, as summarized
in Figure 1. However, clinical studies are needed in order
to develop a well-structured algorithm for the assessment
and treatment of diabetic ulcers to prevent lower-extremity
amputations due to this complication.
7. Basic Conclusions
(i) The four phases of physiological wound healing are:
haemostasis, inflammation, proliferation, and remod-
elling.
(ii) Wound healing in diabetes is impaired by factors
that are both extrinsic and intrinsic to the biology of
wound.
(iii) The standard treatment of diabetic ulcers includes
optimization of glycemic control, extensive debride-
ment, infection elimination, use of moisture dress-
ings, and offloading high pressure.
(iv) Current treatmentmethods in persistent diabetic foot
ulcers include autologous skin transplantation, tissue-
engineered human skin equivalents, bone marrow
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derived cells, growth factors, and subatmospheric
pressure dressings.
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